PE20181051A1 - Anticuerpo anti-epha4 - Google Patents
Anticuerpo anti-epha4Info
- Publication number
- PE20181051A1 PE20181051A1 PE2017002724A PE2017002724A PE20181051A1 PE 20181051 A1 PE20181051 A1 PE 20181051A1 PE 2017002724 A PE2017002724 A PE 2017002724A PE 2017002724 A PE2017002724 A PE 2017002724A PE 20181051 A1 PE20181051 A1 PE 20181051A1
- Authority
- PE
- Peru
- Prior art keywords
- seq
- cdr
- amino acid
- acid sequence
- epha4
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/54—F(ab')2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Neurology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Neurosurgery (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pain & Pain Management (AREA)
- Physics & Mathematics (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Referido a un anticuerpo anti-EphA4 o un fragmento de union a EphA4 del mismo, que comprende: a) CDR-H1 que comprende la secuencia de aminoacidos representada por SEQ ID NO: 26 o la SEQ ID NO: 27; b) CDR-H2 que comprende la secuencia de aminoacidos representada por SEQ ID NO: 28 o la SEQ ID NO: 29; c) CDR-H3 que comprende la secuencia de aminoacidos representada por SEQ ID NO: 30; d) CDR-L1 que comprende la secuencia de aminoacidos representada por SEQ ID NO: 31; e) CDR-L2 que comprende la secuencia de aminoacidos representada por SEQ ID NO: 32; y f) CDR-L3 que comprende la secuencia de aminoacidos representada por SEQ ID NO: 33. En donde dicho anticuerpo es capaz de unirse a EphA4 del mismo e inhibir la union entre EphA4 y su ligando. Tambien se refiere la identificacion de las secuencias de regiones determinantes de complementariedad (CDRs) del anticuerpo anti-EphA4 de raton, y a la preparacion de un anticuerpo humanizado que comprende las secuencias de CDR del anticuerpo antiEphA4 de raton en la region variable de la cadena pesada y la region variable de la cadena ligera. Se utiliza para el tratamiento de la esclerosis lateral amiotrofica (ELA).
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2015177081 | 2015-09-08 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20181051A1 true PE20181051A1 (es) | 2018-07-03 |
Family
ID=58240770
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2017002724A PE20181051A1 (es) | 2015-09-08 | 2016-09-06 | Anticuerpo anti-epha4 |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US10428140B2 (es) |
| EP (1) | EP3381941B1 (es) |
| JP (2) | JP6738814B2 (es) |
| KR (1) | KR20180041136A (es) |
| CN (2) | CN111320693B (es) |
| AR (1) | AR105938A1 (es) |
| AU (1) | AU2016319433A1 (es) |
| BR (1) | BR112018003494A2 (es) |
| CA (1) | CA2989993A1 (es) |
| CO (1) | CO2018000652A2 (es) |
| ES (1) | ES2846175T3 (es) |
| IL (2) | IL256519A (es) |
| MX (2) | MX2018002164A (es) |
| PE (1) | PE20181051A1 (es) |
| PH (1) | PH12018500290A1 (es) |
| RU (2) | RU2719158C2 (es) |
| SG (1) | SG11201800127WA (es) |
| TW (1) | TW201716442A (es) |
| WO (1) | WO2017043466A1 (es) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2020184350A1 (ja) * | 2019-03-08 | 2020-09-17 | 株式会社カネカ | 多能性幹細胞の大量培養 |
| MX2021015298A (es) * | 2019-07-01 | 2022-01-18 | Eisai R&D Man Co Ltd | Anticuerpo anti-epha4 humano. |
| CA3192342A1 (en) * | 2020-12-24 | 2022-06-30 | Eisai R&D Management Co., Ltd. | Anti-epha4 antibody |
| US20240010735A1 (en) | 2020-12-24 | 2024-01-11 | Eisai R&D Management Co., Ltd. | Therapeutic pharmaceutical composition for amyotrophic lateral sclerosis |
| AU2022388189A1 (en) * | 2021-11-11 | 2024-05-02 | Eisai R&D Management Co., Ltd. | Anti-epha4 antibody |
| WO2023088481A1 (en) * | 2021-11-22 | 2023-05-25 | China Medical University | Antibody specific to ephrin type-a receptor 10, fusion protein containing the same, chimeric antigen receptor t-cell expressing the same and uses thereof |
| WO2023122647A2 (en) * | 2021-12-22 | 2023-06-29 | The University Of Chicago | Methods for detecting or treating influenza infections |
| WO2024047558A2 (en) * | 2022-08-31 | 2024-03-07 | Immuneel Therapeutics Private Limited | Antigen-binding proteins and chimeric antigen receptors specific for domain 9 of human cd307e |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4334271B2 (ja) * | 2003-05-07 | 2009-09-30 | セレスター・レキシコ・サイエンシズ株式会社 | 抗体配列作成装置、抗体配列作成方法、プログラム、および、記録媒体 |
| US7604799B2 (en) | 2003-06-06 | 2009-10-20 | Medimmune, Llc | EphA4 Antibodies |
| DE602004031772D1 (de) * | 2003-12-04 | 2011-04-21 | Abbott Biotherapeutics Corp | Anti-ip-10-antikörper |
| EP1733047A2 (en) * | 2004-02-27 | 2006-12-20 | Oncotherapy Science, Inc. | Pin-prc transition genes |
| US20080008719A1 (en) * | 2004-07-10 | 2008-01-10 | Bowdish Katherine S | Methods and compositions for the treatment of prostate cancer |
| EP1662259A1 (en) | 2004-11-25 | 2006-05-31 | Cellzome Ag | Use of Eph receptor inhibitors for the treatment of neurodegenerative diseases |
| CN101432022A (zh) | 2006-02-28 | 2009-05-13 | 肿瘤疗法科学股份有限公司 | 利用抗-EphA4抗体效应物作用损伤细胞的方法 |
| WO2008150010A1 (ja) | 2007-06-08 | 2008-12-11 | Eisai R & D Management Co., Ltd. | γ-セクレターゼの新規基質EphA4を利用したスクリーニング方法 |
| EP2223999B1 (en) * | 2007-11-30 | 2017-10-18 | Eisai R&D Management Co., Ltd. | Epha4 polypeptide having novel activity and use thereof |
| WO2010141974A1 (en) | 2009-06-10 | 2010-12-16 | The University Of Melbourne | Therapeutic applications |
| JP2010285413A (ja) * | 2009-06-10 | 2010-12-24 | Univ Of Melbourne | 治療用途 |
| WO2011042548A1 (en) * | 2009-10-09 | 2011-04-14 | Sanofi-Aventis | Polypeptides for binding to the "receptor for advanced glycation endproducts" as well as compositions and methods involving the same |
| US8865426B2 (en) | 2010-12-17 | 2014-10-21 | Eisai R&D Management Co., Ltd. | Screening method using gelatinase-mediated EphA4 cleavage reaction as an indicator |
| US9784751B2 (en) | 2011-04-25 | 2017-10-10 | Eisai R&D Management Co., Ltd. | Method for detecting neurological disease associated with cognitive impairment by measuring EphA4 extracellular domain |
| GB201107996D0 (en) | 2011-05-13 | 2011-06-29 | Vib Vzw | EphA4 is a diease modifier in motor neuron disease |
| ES2848857T3 (es) * | 2014-07-31 | 2021-08-12 | Us Gov Health & Human Services | Anticuerpos monoclonales humanos contra EphA4 y su uso |
-
2016
- 2016-09-06 BR BR112018003494-0A patent/BR112018003494A2/pt not_active Application Discontinuation
- 2016-09-06 AR ARP160102725A patent/AR105938A1/es unknown
- 2016-09-06 JP JP2017539163A patent/JP6738814B2/ja active Active
- 2016-09-06 TW TW105128767A patent/TW201716442A/zh unknown
- 2016-09-06 MX MX2018002164A patent/MX2018002164A/es unknown
- 2016-09-06 CA CA2989993A patent/CA2989993A1/en not_active Abandoned
- 2016-09-06 US US15/753,611 patent/US10428140B2/en active Active
- 2016-09-06 RU RU2018106456A patent/RU2719158C2/ru active
- 2016-09-06 KR KR1020187004754A patent/KR20180041136A/ko unknown
- 2016-09-06 WO PCT/JP2016/076102 patent/WO2017043466A1/ja active Application Filing
- 2016-09-06 CN CN202010179415.5A patent/CN111320693B/zh active Active
- 2016-09-06 AU AU2016319433A patent/AU2016319433A1/en not_active Abandoned
- 2016-09-06 EP EP16844327.3A patent/EP3381941B1/en active Active
- 2016-09-06 ES ES16844327T patent/ES2846175T3/es active Active
- 2016-09-06 PE PE2017002724A patent/PE20181051A1/es not_active Application Discontinuation
- 2016-09-06 SG SG11201800127WA patent/SG11201800127WA/en unknown
- 2016-09-06 RU RU2019128192A patent/RU2019128192A/ru unknown
- 2016-09-06 CN CN201680048438.4A patent/CN107922499B/zh active Active
-
2017
- 2017-12-24 IL IL256519A patent/IL256519A/en unknown
-
2018
- 2018-01-24 CO CONC2018/0000652A patent/CO2018000652A2/es unknown
- 2018-02-08 PH PH12018500290A patent/PH12018500290A1/en unknown
- 2018-02-20 MX MX2020002406A patent/MX2020002406A/es unknown
-
2019
- 2019-08-23 JP JP2019152823A patent/JP6770153B2/ja active Active
- 2019-08-25 IL IL26888919A patent/IL268889A/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20181051A1 (es) | Anticuerpo anti-epha4 | |
| CO2018004532A2 (es) | Anticuerpos anti-cd19 humano con alta afinidad | |
| CL2020003046A1 (es) | Construcciones de anticuerpo biespecificos que se unen a dll3 y cd3 ( divisional de la solicitud 267-2018) | |
| CY1123212T1 (el) | Συνθεσεις για την αναστολη της ενεργοποιησης του masp-2 εξαρτωμενου συμπληρωματος | |
| AR111630A1 (es) | ANTICUERPOS ANTI-SIRPa | |
| AR106184A1 (es) | Proteínas de unión a pd-1 y sus métodos de uso | |
| PE20221580A1 (es) | Anticuerpos terapeuticos y sus usos | |
| AR109715A1 (es) | Anticuerpos anti-cd27 | |
| PE20191075A1 (es) | Anticuerpo que se une especificamente a il-17a y fragmento funcional del mismo | |
| AR065506A1 (es) | Anticuerpos antagonistas ox40 y su uso en el tratamiento de enfermedades | |
| CL2013003373A1 (es) | Proteina de union al antigeno de maduración de linfocitos b (bcma); composicion farmacéutica que comprende la proteína; uso para preparar un medicamento util para tratar mieloma multiple o (mm) leucemia linfocitica cronica (cll). | |
| NZ625403A (en) | Composition and method for diagnosis and treatment of diseases associated with neurite degeneration | |
| CO6430469A2 (es) | Anticuerpos humanizados que se unen a cd19 y sus usos | |
| PE20120835A1 (es) | Anticuerpos anti-tnf-alfa y sus usos | |
| PE20160553A1 (es) | Anticuerpo antagonista especifico para el heterodimero de alfa-4-beta-7 | |
| PE20191076A1 (es) | Anticuerpo que se une especificamente a pd-1 y fragmento funcional del mismo | |
| ES2570853T3 (es) | Moléculas de anticuerpo humanizadas específicas para IL-31 | |
| RS53405B (en) | CXCR4 HUMANIZED ANTIBODIES FOR CANCER TREATMENT | |
| CO6311009A2 (es) | Anticuerpos monoclonales anti-cd151 de origen murino quimericos y humanizados para inhibir el crecimiento tumoral, secuencias de aminoacidos y nucleicos que los codifican, compuestod derivados o fragmentos funcionales y productos y/o composiciones qu | |
| PE20141547A1 (es) | Anticuerpos neutralizantes frente a las exotoxinas principales tcda y tcdb de clostridium difficile | |
| UA108466C2 (en) | Antibody antagonises c-Met | |
| JP2016527225A5 (es) | ||
| NZ599779A (en) | Compositions and methods for treating inflammatory disorders | |
| PH12017500699A1 (en) | Antibodies that bind to ccr6 and their uses | |
| PE20201255A1 (es) | Anticuerpos y conjugados de anticuerpo-farmaco especificos para cd123 y usos de los mismos |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FX | Voluntary withdrawal |